-

Shareholder Alert: Robbins LLP Announces Acquisition of Inovalon Holdings, Inc. (INOV) by Nordic Capital and Others (Private) May Not Be in Shareholders' Best Interests

SAN DIEGO & BOWIE, Md.--(BUSINESS WIRE)--Robbins LLP announces that it is investigating the acquisition of Inovalon Holdings, Inc. (NASDAQ: INOV) by, among others, Nordic Capital X, and Inovalon's CEO and founder Keith Dunleavy, M.D. (the "Investor Consortium"), who currently owns and controls 64% of Inovalon's outstanding stock. Under the terms of the agreement, the Investor Consortium will acquire Inovalon in a going private merger and each Inovalon shareholder will receive just $41.00 per share in cash in exchange for each share of Inovalon.

If you own shares of Inovalon Holdings, Inc., click here.

Is the Proposed Acquisition Best for Inovalon Holdings, Inc. (INOV) and Its Shareholders?

According to the Proxy Statement, Inovalon's board approved a merger agreement with the Investor Consortium to take Inovalon private. The deal is valued at approximately $7.3 billion and is expected to close in late 2021 or early 2022. Upon completion of the transaction, Inovalon will become a private company, with Dr. Dunleavy continuing as a substantial shareholder and retaining his positions as a board member and CEO. Robbins LLP is concerned that Inovalon's board of directors engaged in an unfair process and agreed to an unfair amount to be paid to shareholders.

Inovalon Holdings, Inc. (INOV) Shareholders Have Legal Options

Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in securities litigation and shareholder rights law. The law firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:INOV

Release Summary
Acquisition of Inovalon Holdings, Inc (INOV) by Nordic Capital and Others May Not Be in Shareholders' Best Interests 
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Notice: Robbins LLP Informs Investors of the Super Micro Computer, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Super Micro Computer, Inc. (NASDAQ: SMCI) securities between April 30, 2024 and March 19, 2026. Super Micro is a technology company that designs, develops, and manufactures high-performance server and storage systems, primarily for artificial intelligence (“AI”), data center, and cloud solutions customers. For more information, submit a form,...

BlackRock TCP Capital Corp. Investor Alert - TCPC Stockholders with Large Losses Should Contact Robbins LLP for Information About the Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired BlackRock TCP Capital Corp. (NASDAQ: TCPC) securities between November 6, 2024 and January 23, 2026. BlackRock TCP is a business development company that raises funds from investors and then uses those funds to make loans to small and midsize businesses as an alternative to bank financing. For more information, submit a form, email attorney Aa...

MREO Investor Alert - Mereo BioPharma Group plc Investors with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Mereo BioPharma Group plc. (NASDAQ: MREO) American Depository Shares ("ADS") between June 5, 2023 and December 26, 2025. Mereo is a biopharmaceutical company focused on the development of therapeutics for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the alleg...
Back to Newsroom